Astex Pharmaceuticals Announces Oral Presentation of SGI-110 Data at the Upcoming European Cancer Congress (ECCO-ESMO-ESTRO)

Astex Pharmaceuticals Announces Oral Presentation of SGI-110 Data at the Upcoming European Cancer Congress (ECCO-ESMO-ESTRO)

Astex Pharmaceuticals Announces Presentation of Updated Results of SGI-110-01 Study inPatients With Intermediate or High Risk Relapsed or Refractory Myelodysplastic Syndromes at the European Hematology Association

Astex Pharmaceuticals Announces Presentation of Updated Results of SGI-110-01 Study in Patients With Intermediate or High Risk Relapsed or Refractory Myelodysplastic Syndromes at the European Hematology Association

Astex Pharmaceuticals to Announce 2012 Fourth Quarter and Year-End Financial Results on February 25th

Astex Pharmaceuticals to Announce 2012 Fourth Quarter and Year-End Financial Results on February 25th

Cancer Research UK and Cancer Research Technology Initiate AT13148 Clinical Trial to Treat Several Cancer Types

Cancer Research UK and Cancer Research Technology Initiate AT13148 Clinical Trial to Treat Several Cancer Types

Astex Pharmaceuticals Announces Initiation of SGI-110 Phase 2 Trial in Advanced Hepatocellular Carcinoma (HCC) Patients

Astex Pharmaceuticals Announces Initiation of SGI-110 Phase 2 Trial in Advanced Hepatocellular Carcinoma (HCC) Patients